Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals

Synapse

Volumn 63, Issue 12, 2009, Pages 1133-1142

  Qi, Zhen ^a   Miller, Gary W ^a,b   Voit, Eberhard O ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

Biochemical Systems Theory; Dopamine metabolism; Dopamine nerve terminal; Metabolic profile; Monte Carlo method; Parkinson's disease; Personalized medicine

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); CATALASE; CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE TRANSPORTER; FERROUS ION; GLUTATHIONE; GLUTATHIONE PEROXIDASE; S ADENOSYLMETHIONINE; SUPEROXIDE DISMUTASE; VESICULAR MONOAMINE TRANSPORTER 2;

ARTICLE; DOPAMINE METABOLISM; MATHEMATICAL MODEL; NERVE ENDING; PRIORITY JOURNAL;

3,4-DIHYDROXYPHENYLACETIC ACID; CATECHOL O-METHYLTRANSFERASE; COMPUTER SIMULATION; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; EXTRACELLULAR SPACE; HUMANS; IRON; MODELS, NEUROLOGICAL; MONOAMINE OXIDASE; MONTE CARLO METHOD; NEURONS; QUINONES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 70349859885     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20686     Document Type: Article

References (32)

1. Alvarez-Vasquez F, Sims KJ, Cowart LA, Okamoto Y, Voit EO, Hannun YA. 2005. Simulation and validation of modelled sphingolipid metabolism in Saccharomyces cerevisiae. Nature 433:425-430. (Pubitemid 40203323)
2. Andersen JK. 2004. Iron dysregulation and Parkinson's disease. J Alzheimers Dis 6(6 Suppl):S47-S52.
3. Carlsson A. 1978. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 135:165-173.
4. Carlsson A. 1988. The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179-186. (Pubitemid 19126130)
5. Caudle WM, Richardson JR, Wang MZ, Taylor TN, Guillot TS, McCormack AL, Colebrooke RE, Di Monte DA, Emson PC, Miller GW. 2007. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 27:8138-8148.
6. Colebrooke RE, Humby T, Lynch PJ, McGowan DP, Xia J, Emson PC. 2006. Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease. Eur J Neurosci 24:2622-2630. (Pubitemid 44726774)
7. Fernandez HH, Chen JJ. 2007. Monamine oxidase inhibitors: Current and emerging agents for Parkinson disease. Clin Neuropharmacol 30:150-168. (Pubitemid 46871865)
8. Gerlach M, Double K, Riederer P, Hirsch E, Jellinger K, Jenner P, Trautwein A, Youdim MB. 1997. Iron in the Parkinsonian substantia nigra. Mov Disord 12:258-260.
9. Glatt CE, Wahner AD, White DJ, Ruiz-Linares A, Ritz B. 2006. Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women. Hum Mol Genet 15:299-305. (Pubitemid 43125983)
10. Graham DG. 1978. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-643.
11. Hanson GR, Sandoval V, Riddle E, Fleckenstein AE. 2004. Psychostimulants and vesicle trafficking: A novel mechanism and therapeutic implications. Ann N Y Acad Sci 1025:146-150. (Pubitemid 39643857)
12. Kaur D, Peng J, Chinta SJ, Rajagopalan S, Di Monte DA, Cherny RA, Andersen JK. 2007. Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging 28:907-913. (Pubitemid 46589736)
13. Levy F. 1991. The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust N Z J Psychiatry 25:277-283.
14. Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AH. 1994. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 36:876-881. (Pubitemid 24370927)
15. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA. 1998. Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: Evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18:8417-8422.
16. Mooslehner KA, Chan PM, Xu W, Liu L, Smadja C, Humby T, Allen ND, Wilkinson LS, Emson PC. 2001. Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: Potential mouse model for parkinsonism. Mol Cell Biol 21:5321-5331.
17. Qi Z, Miller GW, Voit EO. 2008a. Computational systems analysis of dopamine metabolism. PLoS ONE 3:e2444.
18. Qi Z, Miller GW, Voit EO. 2008b. A mathematical model of presynaptic dopamine homeostasis: Implications for schizophrenia. Pharmacopsychiatry 41(Suppl 1):S89-S98.
19. Savageau MA. 1969a. Biochemical systems analysis. I. Some mathematical properties of the rate law for the component enzymatic reactions. J Theor Biol 25:365-369.
20. Savageau MA. 1969b. Biochemical systems analysis. II. The steadystate solutions for an n-pool system using a power-law approximation. J Theor Biol 25:370-379.
21. Savageau MA. 1970. Biochemical systems analysis. 3. Dynamic solutions using a power-law approximation. J Theor Biol 26:215-226.
22. Savageau MA. 1976. Biochemical systems analysis: A study of function and design in molecular biology. Reading, MA: Addison- Wesley. 199 p.
23. Stocchi F, Vacca L, Grassini P, De Pandis MF, Battaglia G, Cattaneo C, Fariello RG. 2006. Symptom relief in Parkinson disease by safi- namide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology 67(7 Suppl 2):S24-S29. (Pubitemid 44568831)
24. Stokes AH, Hastings TG, Vrana KE. 1999. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 55:659-665.
25. Swanson JM, Kinsbourne M, Nigg J, Lanphear B, Stefanatos GA, Volkow N, Taylor E, Casey BJ, Castellanos FX, Wadhwa PD. 2007. Etiologic subtypes of attention-deficit/hyperactivity disorder: Brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol Rev 17:39-59. (Pubitemid 46355008)
26. Takahashi N, Miner LL, Sora I, Ujike H, Revay RS, Kostic V, Jackson-Lewis V, Przedborski S, Uhl GR. 1997. VMAT2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Natl Acad Sci USA 94:9938-9943. (Pubitemid 27408169)
27. Torres NV, Voit EO. 2002. Pathway analysis and optimization in metabolic engineering. Cambridge, UK: Cambridge University Press. xiv + 305 p.
28. Tyce GM, Dousa MK, Muenter MD. 1990. MAO and L-dopa treatment of Parkinson's disease. J Neural Transm Suppl 29:233-239.
29. Voit EO, editor. 1991. Canonical nonlinear modeling. S-System approach to understanding complexity. New York, NY: Van Nostrand Reinhold. xi + 365 p.
30. Voit EO. 2000a. Canonical modeling: Review of concepts with emphasis on environmental health. Environ Health Perspect 108(Suppl 5):895-909.
31. Voit EO. 2000b. Computational analysis of biochemical systems: A practical guide for biochemists and molecular biologists. Cambridge, UK: Cambridge University Press. xii + 531 p.
32. Youdim MB, Bakhle YS. 2006. Monoamine oxidase: Isoforms and inhibitors in Parkinson's disease and depressive illness. Br J Pharmacol 147(Suppl 1):S287-S296. (Pubitemid 43077287)